ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 117 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 2.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2015 | $3,014,000 | -1.6% | 67,000 | -33.0% | 0.47% | +9.6% |
| Q1 2015 | $3,062,000 | -19.2% | 100,000 | +34.2% | 0.42% | -20.7% |
| Q4 2014 | $3,788,000 | +4.6% | 74,500 | -18.6% | 0.54% | -3.6% |
| Q3 2014 | $3,621,000 | -8.1% | 91,500 | 0.0% | 0.56% | -8.3% |
| Q2 2014 | $3,941,000 | +32.6% | 91,500 | +23.1% | 0.61% | +28.7% |
| Q1 2014 | $2,971,000 | +19.8% | 74,306 | -18.2% | 0.47% | +17.8% |
| Q4 2013 | $2,479,000 | -17.1% | 90,866 | -30.4% | 0.40% | -29.6% |
| Q3 2013 | $2,990,000 | – | 130,466 | – | 0.57% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |